Julian Suhrer, MD
Obstetrics & Gynecology · Jacksonville, FLNPI 1538152152
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Evofem Biosciences, Inc. at 29.0% of the total. Reporting peaked in 2022 at $492 and has fallen 52.8% since, to $232 in 2025.
Across 114 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Evofem Biosciences, Inc.$652
- Exeltis, USA Inc.$207
- Hologic Sales And Service, LLC$154
- Bayer$113
- Lupin Inc.$103
- Mayne Pharma Commercial LLC$94
- plus $931 from 23 others
What the payments were for
- Food & beverage$2,22499%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Evofem Biosciences, Inc. | 33 | $652 |
| Exeltis, USA Inc. | 12 | $207 |
| Hologic Sales And Service, LLC | 6 | $154 |
| Bayer | 5 | $113 |
| Lupin Inc. | 6 | $103 |
| Mayne Pharma Commercial LLC | 6 | $94 |
| AbbVie(2 entities) | 4 | $78 |
| Minerva Surgical, Inc | 1 | $70 |
| Agile Therapeutics, Inc. | 4 | $62 |
| Astellas Pharma US Inc | 3 | $59 |
| Millicent US Inc | 3 | $59 |
| Therapeuticsmd, Inc. | 3 | $59 |
| Exact Sciences | 3 | $53 |
| Myovant Sciences Inc. | 2 | $49 |
| BD | 2 | $48 |
| LSI Solutions Inc | 2 | $47 |
| Pfizer | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Shield Therapeutics Inc | 1 | $38 |
| Dysis Medical, Inc. | 2 | $33 |
| Scynexis, Inc. | 2 | $31 |
| AMAG Pharmaceuticals, Inc. | 2 | $28 |
| Covidien LP | 1 | $27 |
| Roche Diagnostics Corporation | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Organon | 1 | $14 |
| Avion Pharmaceuticals | 1 | $12 |
| Smith+Nephew | 1 | $12 |
How this compares
$2,253 in reported general payments places this provider in the 70th percentile of 2,438 obstetrics & gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 17 | $1,925 |
| Clindamycin Phosphate | 28 | $1,656 |
| Terconazole | 15 | $300 |
| Triamcinolone Acetonide | 44 | $235 |
| ValacyclovirValacyclovir Hcl | 12 | $224 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $168 |
| ProgesteroneProgesterone, Micronized | 11 | $141 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Jacksonville
- David MillerJacksonville$26K
- Steven McCarusCelebration$2.3M
- Elliot CazesTampa$725K
- Charles BloomWinter Park$652K
- Jay CohenPlantation$556K
- Omar ZwainWinter Park$531K
- Keith AquaWellington$473K
- Jeffrey KotzenPalm Beach Gardens$413K
- Glenn BankertCrestview$388K
- Erica StockwellCelebration$321K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.